Browsing Tag
ROS1-positive NSCLC
2 posts
Nuvalent (NASDAQ: NUVL) sharpens zidesamtinib case at AACR 2026 with post-TKI ROS1 lung cancer data
Nuvalent’s AACR 2026 zidesamtinib data could reshape the ROS1 NSCLC treatment debate ahead of its FDA decision. Read what it means now.
Why updated TRUST-I and TRUST-II results make IBTROZI a top contender in targeted lung cancer therapy
Nuvation Bio unveils pivotal TRUST-I and TRUST-II updates for IBTROZI in ROS1+ lung cancer, showing strong durability and brain response. Read more now.